CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 216 enrolled
Drug / intervention
ACE inhibitor, angiotensin receptor blockerdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04353596
NCT04353596Phase 4Completed
CompareCT.gov

Stopping ACE-inhibitors in COVID-19: A Randomized Controlled Trial

Medical University Innsbruck·interventional·Posted Apr 20, 2020·Updated Sep 13, 2022

In Brief

A Phase 4 clinical trial evaluating ACE inhibitor, angiotensin receptor blocker for SARS-CoV-2 and COVID-19. Completed, enrolled 216 participants across 31 sites in 2 countries.

Detailed Summary

ACEI-COVID-19 is a multicenter, randomized trial testing the hypothesis that stopping/replacing chronic treatment with ACE-inhibitors (ACEI) or angiotensin receptor blockers (ARB) improves outcomes in symptomatic SARS-CoV2-infected patients

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSARS-CoV-2, COVID-19
CountriesAustria, Germany
CollaboratorsLudwig-Maximilians - University of Munich, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedApr 20, 2020
Enrollment StartApr 20, 2020
Primary CompletionFeb 16, 2021
Study CompletionFeb 24, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.2 years ago

Interventions

ACE inhibitor, angiotensin receptor blockerdrug

In patients randomized to stopping / replacing ACEI or ARB, it may be necessary to switch to another drug without direct effect on the RAS system. In patients, randomized to continuation, it may be needed to stop ACEI or ARB (e.g. hypotension with beginning sepsis) irrespective of the study.